<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32397320</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Creatine Kinase and Progression Rate in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1174</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells9051174</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis <b>(</b>ALS) is a neurodegenerative disease with no recognized clinical prognostic factor. Creatinine kinase (CK) increase in these patients is already described with conflicting results on prognosis and survival. In 126 ALS patients who were fast or slow disease progressors, CK levels were assayed for 16 months every 4 months in an observational case-control cohort study with prospective data collection conducted in Italy. CK was also measured at baseline in 88 CIDP patients with secondary axonal damage and in two mouse strains (129SvHSD and C57-BL) carrying the same SOD1G93A transgene expression but showing a fast (129Sv-SOD1G93A) and slow (C57-SOD1G93A) ALS progression rate. Higher CK was found in ALS slow progressors compared to fast progressors in T1, T2, T3, and T4, with a correlation with Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores. Higher CK was found in spinal compared to bulbar-onset patients. Transgenic and non-transgenic C57BL mice showed higher CK levels compared to 129SvHSD strain. At baseline mean CK was higher in ALS compared to CIDP. CK can predict the disease progression, with slow progressors associated with higher levels and fast progressors to lower levels, in both ALS patients and mice. CK is higher in ALS patients compared to patients with CIDP with secondary axonal damage; the higher levels of CK in slow progressors patients, but also in C57BL transgenic and non-transgenic mice designs CK as a predisposing factor for disease rate progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceccanti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzilli</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cambieri</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libonati</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onesti</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frasca</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorini</LastName><ForeName>Ilenia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucci</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Rare Diseases, San Camillo Forlanini Hospital, 00152 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garibaldi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromuscular Disease Centre, Department of Neurology, Mental Health and Sensory Organs (NESMOS), Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Famacologiche Mario Negri-IRCCS, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbrizio</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Famacologiche Mario Negri-IRCCS, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trolese</LastName><ForeName>Maria Chiara</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Laboratory Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Famacologiche Mario Negri-IRCCS, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Famacologiche Mario Negri-IRCCS, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inghilleri</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rare Neuromuscular Diseases Centre, Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009211">Myoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009211" MajorTopicYN="N">Myoglobin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CK</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">chronic inflammatory demyelinating polyneuropathy</Keyword><Keyword MajorTopicYN="N">creatine kinase</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32397320</ArticleId><ArticleId IdType="pmc">PMC7291088</ArticleId><ArticleId IdType="doi">10.3390/cells9051174</ArticleId><ArticleId IdType="pii">cells9051174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor B.J., Codd M.B., Corr B., Forde C., Frost E., Hardiman O.M. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch. Neurol. 2000;57:1171&#x2013;1176. doi: 10.1001/archneur.57.8.1171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.8.1171</ArticleId><ArticleId IdType="pubmed">10927797</ArticleId></ArticleIdList></Reference><Reference><Citation>Berardelli A., Inghilleri M., Formisano R., Accornero N., Manfredi M. Stimulation of motor tracts in motor neuron disease. J. Neurol. Neurosurg. Psychiatry. 1987;50:732&#x2013;737. doi: 10.1136/jnnp.50.6.732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.50.6.732</ArticleId><ArticleId IdType="pmc">PMC1032079</ArticleId><ArticleId IdType="pubmed">3612154</ArticleId></ArticleIdList></Reference><Reference><Citation>Libonati L., Barone T.F., Ceccanti M., Cambieri C., Tartaglia G., Onesti E., Petrucci A., Frasca V., Inghilleri M. Heteronymous H reflex in temporal muscle as sign of hyperexcitability in ALS patients. Clin. Neurophysiol. 2019;130:1455&#x2013;1459. doi: 10.1016/j.clinph.2019.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.05.010</ArticleId><ArticleId IdType="pubmed">31164256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruoppolo G., Schettino I., Frasca V., Giacomelli E., Prosperini L., Cambieri C., Roma R., Greco A., Mancini P., De Vincentiis M., et al. Dysphagia in amyotrophic lateral sclerosis: Prevalence and clinical findings. Acta Neurol. Scand. 2013;128:397&#x2013;401. doi: 10.1111/ane.12136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12136</ArticleId><ArticleId IdType="pubmed">23668293</ArticleId></ArticleIdList></Reference><Reference><Citation>Truini A., Biasiotta A., Onesti E., Di Stefano G., Ceccanti M., La Cesa S., Pepe A., Giordano C., Cruccu G., Inghilleri M. Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS. J. Neurol. 2015;262:1014&#x2013;1018. doi: 10.1007/s00415-015-7672-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7672-0</ArticleId><ArticleId IdType="pubmed">25683764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccanti M., Onesti E., Rubino A., Cambieri C., Tartaglia G., Miscioscia A., Frasca V., Inghilleri M. Modulation of human corticospinal excitability by paired associative stimulation in patients with amyotrophic lateral sclerosis and effects of Riluzole. Brain Stimul. 2018;11:775&#x2013;781. doi: 10.1016/j.brs.2018.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2018.02.007</ArticleId><ArticleId IdType="pubmed">29459142</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu T., Zhang Y., Tang X., Liu X., Wang Y., Zhou C., Luo C., Zhang J. Precentral degeneration and cerebellar compensation in amyotrophic lateral sclerosis: A multimodal MRI analysis. Hum. Brain Mapp. 2019;40:3464&#x2013;3474. doi: 10.1002/hbm.24609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24609</ArticleId><ArticleId IdType="pmc">PMC6865414</ArticleId><ArticleId IdType="pubmed">31020731</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 2015;51:14&#x2013;18. doi: 10.1002/mus.24470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24470</ArticleId><ArticleId IdType="pmc">PMC4270289</ArticleId><ArticleId IdType="pubmed">25288265</ArticleId></ArticleIdList></Reference><Reference><Citation>Said G., Krarup C. Chronic inflammatory demyelinative polyneuropathy. Handb. Clin. Neurol. 2013;115:403&#x2013;413. doi: 10.1016/B978-0-444-52902-2.00022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-52902-2.00022-9</ArticleId><ArticleId IdType="pubmed">23931792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima A.F., Evangelista T., de Carvalho M. Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyogr. Clin. Neurophysiol. 2003;43:189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">12712806</ArticleId></ArticleIdList></Reference><Reference><Citation>Panitch H.S., Franklin G.M. Elevation of serum creatine phosphokinase in amyotrophic lateral sclerosis. Neurology. 1972;22:964&#x2013;966. doi: 10.1212/WNL.22.9.964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.22.9.964</ArticleId><ArticleId IdType="pubmed">4673382</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrit A.N., Anderson M.S. Serum creatine phosphokinase in amyotrophic lateral sclerosis. Correlation with sex, duration, and skeletal muscle biopsy. Neurology. 1974;24:834&#x2013;837. doi: 10.1212/wnl.24.9.834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.24.9.834</ArticleId><ArticleId IdType="pubmed">4859480</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds P.J., Ziegler D.K. Diagnostic value of serum creatine phosphokinase in motor neuron disease. South. Med. J. 1975;68:1388&#x2013;1390. doi: 10.1097/00007611-197511000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007611-197511000-00016</ArticleId><ArticleId IdType="pubmed">171774</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington T.M., Cohen M.D., Bartleson J.D., Ginsburg W.W. Elevation of creatine kinase in amyotrophic lateral sclerosis. Potential confusion with polymyositis. Arthritis Rheum. 1983;26:201&#x2013;205. doi: 10.1002/art.1780260212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780260212</ArticleId><ArticleId IdType="pubmed">6824516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinaki M., Mulder D.W. Amyotrophic lateral sclerosis: Relationship between serum creatine kinase level and patient survival. Arch. Phys. Med. Rehabil. 1986;67:169&#x2013;171. doi: 10.1016/0003-9993(86)90064-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9993(86)90064-X</ArticleId><ArticleId IdType="pubmed">3954579</ArticleId></ArticleIdList></Reference><Reference><Citation>Felice K.J., North W.A. Creatine kinase values in amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;160:S30&#x2013;S32. doi: 10.1016/S0022-510X(98)00195-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00195-6</ArticleId><ArticleId IdType="pubmed">9851645</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;ssmuth S.D., Tumani H., Ecker D., Ludolph A.C. Amyotrophic lateral sclerosis: Disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett. 2003;353:57&#x2013;60. doi: 10.1016/j.neulet.2003.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.09.018</ArticleId><ArticleId IdType="pubmed">14642437</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahin N., Sorenson E.J. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40:126&#x2013;129. doi: 10.1002/mus.21310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21310</ArticleId><ArticleId IdType="pubmed">19533663</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson S.B., Kasarskis E.J., Hu N., Pulst S.-M., Mendiondo M.S., Matthews D.E., Mitsumoto H., Tandan R., Simmons Z., Kryscio R.J., et al. Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotroph. Lateral Scler. Front. Degener. 2015;16:473&#x2013;477. doi: 10.3109/21678421.2015.1062516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062516</ArticleId><ArticleId IdType="pmc">PMC5595062</ArticleId><ArticleId IdType="pubmed">26312548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq M.K., Lee E., Bradburn M., McDermott C.J., Shaw P.J. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:1071&#x2013;1078. doi: 10.1111/ene.12995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12995</ArticleId><ArticleId IdType="pubmed">27029589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H., Cui L., Guan Y., Liu M., Li X., Shen D., Li D., Cui B., Fang J., Ding Q., et al. Correlation of Creatine Kinase Levels with Clinical Features and Survival in Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:322. doi: 10.3389/fneur.2017.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00322</ArticleId><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H., Cui L., Liu M., Guan Y., Li X., Shen D., Zhang K., Liu S., Wu S., Ding Q., et al. Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis. Clin. Neurophysiol. 2018;129:926&#x2013;930. doi: 10.1016/j.clinph.2018.01.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.01.071</ArticleId><ArticleId IdType="pubmed">29550653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallimann T., Wyss M., Brdiczka D., Nicolay K., Eppenberger H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The &#x201c;phosphocreatine circuit&#x201d; for cellular energy homeostasis. Biochem. J. 1992;281:21&#x2013;40. doi: 10.1042/bj2810021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2810021</ArticleId><ArticleId IdType="pmc">PMC1130636</ArticleId><ArticleId IdType="pubmed">1731757</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadam-Kia S., Oddis C.V., Aggarwal R. Approach to asymptomatic creatine kinase elevation. Clevel. Clin. J. Med. 2016;83:37&#x2013;42. doi: 10.3949/ccjm.83a.14120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.83a.14120</ArticleId><ArticleId IdType="pmc">PMC4871266</ArticleId><ArticleId IdType="pubmed">26760521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittenberg J.B., Wittenberg B.A. Myoglobin function reassessed. J. Exp. Biol. 2003;206:2011&#x2013;2020. doi: 10.1242/jeb.00243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jeb.00243</ArticleId><ArticleId IdType="pubmed">12756283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordway G.A., Garry D.J. Myoglobin: An essential hemoprotein in striated muscle. J. Exp. Biol. 2004;207:3441&#x2013;3446. doi: 10.1242/jeb.01172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jeb.01172</ArticleId><ArticleId IdType="pubmed">15339940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagawa N., Hizawa K. Immunohistochemical study of myoglobin in neuromuscular diseases. Muscle Nerve. 1985;8:9&#x2013;16. doi: 10.1002/mus.880080103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880080103</ArticleId><ArticleId IdType="pubmed">3903489</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y. Radioimmunoassay and immunohistochemical study of myoglobin in neuromuscular diseases. Zhonghua Yi Xue Za Zhi. 1992;72:144&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">1319805</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F.Y. Rhabdomyolysis: A review of the literature. Neth. J. Med. 2009;67:272&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">19841484</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M., Papa S., Crippa V., Nardo G., Peviani M., Cheroni C., Trolese M.C., Lauranzano E., Bonetto V., Poletti A., et al. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:492&#x2013;504. doi: 10.1016/j.neurobiolaging.2014.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.06.026</ArticleId><ArticleId IdType="pubmed">25085783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., Tortarolo M., Vallarola A., Freschi M., Pasetto L., Bonetto V., Bendotti C. New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models. Brain Pathol. 2016;26:237&#x2013;247. doi: 10.1111/bpa.12351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12351</ArticleId><ArticleId IdType="pubmed">26780365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Trolese M.C., de Vito G., Cecchi R., Riva N., Dina G., Heath P.R., Quattrini A., Shaw P.J., Piazza V., et al. Immune response in peripheral axons delays disease progression in SOD1G93A mice. J. Neuroinflamm. 2016;13:261. doi: 10.1186/s12974-016-0732-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0732-2</ArticleId><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society&#x2014;First revision. J. Peripher. Nerv. Syst. 2010;15:185&#x2013;195. doi: 10.1111/j.1529-8027.2010.00278.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1529-8027.2010.00278.x</ArticleId><ArticleId IdType="pubmed">21040140</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce N.C., Oskarsson B., Jin L.-W. Muscle biopsy evaluation in neuromuscular disorders. Phys. Med. Rehabil. Clin. N. Am. 2012;23:609&#x2013;631. doi: 10.1016/j.pmr.2012.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmr.2012.06.006</ArticleId><ArticleId IdType="pmc">PMC4590778</ArticleId><ArticleId IdType="pubmed">22938878</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S., King A., Cleveland M., Pradat P.-F., Corse A., Rothstein J.D., Leigh P.N., Abila B., Bates S., Wurthner J., et al. Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol. Commun. 2014;2:165. doi: 10.1186/s40478-014-0165-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0165-z</ArticleId><ArticleId IdType="pmc">PMC4297389</ArticleId><ArticleId IdType="pubmed">25510661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzaccara C., Labruna G., Cito G., Scarf&#xf2; M., De Felice M., Pastore L., Sacchetti L. Age-Related Reference Intervals of the Main Biochemical and Hematological Parameters in C57BL/6J, 129SV/EV and C3H/HeJ Mouse Strains. PLoS ONE. 2008;3:e3772. doi: 10.1371/journal.pone.0003772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003772</ArticleId><ArticleId IdType="pmc">PMC2582346</ArticleId><ArticleId IdType="pubmed">19020657</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G., Iennaco R., Fusi N., Heath P.R., Marino M., Trolese M.C., Ferraiuolo L., Lawrence N., Shaw P.J., Bendotti C. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain. 2013;136:3305&#x2013;3332. doi: 10.1093/brain/awt250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt250</ArticleId><ArticleId IdType="pubmed">24065725</ArticleId></ArticleIdList></Reference><Reference><Citation>George M.D., McGill N.-K., Baker J.F. Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the normal range. Medicine (Baltimore) 2016;95:e4344. doi: 10.1097/MD.0000000000004344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000004344</ArticleId><ArticleId IdType="pmc">PMC5370787</ArticleId><ArticleId IdType="pubmed">27537560</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong E.T., Cobb C., Umehara M.K., Wolff G.A., Haywood L.J., Greenberg T., Shaw S.T. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am. J. Clin. Pathol. 1983;79:582&#x2013;586. doi: 10.1093/ajcp/79.5.582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/79.5.582</ArticleId><ArticleId IdType="pubmed">6837521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S., Hardiman O., Traynor B.J. Ethnic variation in the incidence of ALS: A systematic review. Neurology. 2007;68:1002&#x2013;1007. doi: 10.1212/01.wnl.0000258551.96893.6f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000258551.96893.6f</ArticleId><ArticleId IdType="pubmed">17389304</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri S., Langefeld C.D., Milligan C., Caress J.B., Cartwright M.S. Racial differences in intervention rates in individuals with ALS. Neurology. 2019;92:e1969&#x2013;e1974. doi: 10.1212/WNL.0000000000007366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007366</ArticleId><ArticleId IdType="pmc">PMC6511079</ArticleId><ArticleId IdType="pubmed">30918092</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts A.L., Johnson N.J., Chen J.T., Cudkowicz M.E., Weisskopf M.G. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology. 2016;87:2300&#x2013;2308. doi: 10.1212/WNL.0000000000003298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003298</ArticleId><ArticleId IdType="pmc">PMC5135021</ArticleId><ArticleId IdType="pubmed">27742817</ArticleId></ArticleIdList></Reference><Reference><Citation>Csillik B., Nemcs&#xf3;k J., Chase B., Csillik A.E., Knyih&#xe1;r-Csillik E. Infraterminal spreading and extrajunctional expression of nicotinic acetylcholine receptors in denervated rat skeletal muscle. Exp. Brain Res. 1999;125:426&#x2013;434. doi: 10.1007/s002210050699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002210050699</ArticleId><ArticleId IdType="pubmed">10323288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashley Z., Sutherland H., Lanm&#xfc;ller H., Russold M.F., Unger E., Bijak M., Mayr W., Boncompagni S., Protasi F., Salmons S., et al. Atrophy, but not necrosis, in rabbit skeletal muscle denervated for periods up to one year. Am. J. Physiol. Cell Physiol. 2007;292:C440&#x2013;C451. doi: 10.1152/ajpcell.00085.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00085.2006</ArticleId><ArticleId IdType="pubmed">17218372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiessling W.R., Ricker K., Pflughaupt K.W., Mertens H.G., Haubitz I. Serum myoglobin in primary and secondary skeletal muscle disorders. J. Neurol. 1981;224:229&#x2013;233. doi: 10.1007/BF00313285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313285</ArticleId><ArticleId IdType="pubmed">6162019</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E., Inghilleri M., Conti L., Deflorio C., Frasca V., Manteca A., Pichiorri F., Roseti C., Torchia G., Limatola C., et al. Physiological characterization of human muscle acetylcholine receptors from ALS patients. Proc. Natl. Acad. Sci. USA. 2011;108:20184&#x2013;20188. doi: 10.1073/pnas.1117975108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1117975108</ArticleId><ArticleId IdType="pmc">PMC3250127</ArticleId><ArticleId IdType="pubmed">22128328</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E., Reyes-Ruiz J.M., Lopergolo D., Roseti C., Bertollini C., Ruffolo G., Cifelli P., Onesti E., Limatola C., Miledi R., et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. USA. 2016;113:3060&#x2013;3065. doi: 10.1073/pnas.1600251113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600251113</ArticleId><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Musar&#xf2; A., Dobrowolny G., Cambieri C., Onesti E., Ceccanti M., Frasca V., Pisano A., Cerbelli B., Lepore E., Ruffolo G., et al. Neuromuscular magnetic stimulation counteracts muscle decline in ALS patients: Results of a randomized, double-blind, controlled study. Sci. Rep. 2019;9:2837. doi: 10.1038/s41598-019-39313-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39313-z</ArticleId><ArticleId IdType="pmc">PMC6391419</ArticleId><ArticleId IdType="pubmed">30808899</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>